- Home
- LPTH vs DAWN Comparison
LPTH vs DAWN Comparison
Compare LPTH & DAWN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPTH
- DAWN
- Stock Information
- Founded
- LPTH 1985
- DAWN 2018
- Country
- LPTH United States
- DAWN United States
- Employees
- LPTH N/A
- DAWN N/A
- Industry
- LPTH Semiconductors
- DAWN Biotechnology: Pharmaceutical Preparations
- Sector
- LPTH Technology
- DAWN Health Care
- Exchange
- LPTH Nasdaq
- DAWN Nasdaq
- Market Cap
- LPTH N/A
- DAWN 1.3B
- IPO Year
- LPTH 1996
- DAWN 2021
- Fundamental
- Price
- LPTH $2.69
- DAWN $12.79
- Analyst Decision
- LPTH Strong Buy
- DAWN Strong Buy
- Analyst Count
- LPTH 2
- DAWN 7
- Target Price
- LPTH $3.00
- DAWN $36.17
- AVG Volume (30 Days)
- LPTH 356.6K
- DAWN 937.9K
- Earning Date
- LPTH 02-06-2025
- DAWN 10-30-2024
- Dividend Yield
- LPTH N/A
- DAWN N/A
- EPS Growth
- LPTH N/A
- DAWN N/A
- EPS
- LPTH N/A
- DAWN N/A
- Revenue
- LPTH $32,049,325.00
- DAWN $101,953,000.00
- Revenue This Year
- LPTH $12.63
- DAWN N/A
- Revenue Next Year
- LPTH $16.80
- DAWN $36.10
- P/E Ratio
- LPTH N/A
- DAWN N/A
- Revenue Growth
- LPTH N/A
- DAWN N/A
- 52 Week Low
- LPTH $1.04
- DAWN $11.94
- 52 Week High
- LPTH $2.86
- DAWN $18.07
- Technical
- Relative Strength Index (RSI)
- LPTH 84.03
- DAWN 39.97
- Support Level
- LPTH $2.36
- DAWN $12.26
- Resistance Level
- LPTH $2.86
- DAWN $12.81
- Average True Range (ATR)
- LPTH 0.23
- DAWN 0.52
- MACD
- LPTH 0.09
- DAWN -0.05
- Stochastic Oscillator
- LPTH 84.68
- DAWN 28.94
About DAWN Day One Biopharmaceuticals Inc.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, kinase inhibitor.